Decitabine Increases Neoantigen and Cancer Testis Antigen Expression to Enhance T Cell-Mediated Toxicity Against Glioblastoma

Strategic Insights -

Researchers from the University of Oxford have discovered that decitabine, a DNA methyltransferase inhibitor, can increase the expression of neoantigens and cancer testis antigens in glioblastoma cells, making them more susceptible to T cell-mediated toxicity. This breakthrough finding has significant implications for the treatment of glioblastoma, a highly aggressive and malignant brain cancer with a poor prognosis.

Key Takeaways:

  • Decitabine treatment increases the expression of neoantigens and cancer testis antigens in glioblastoma cells, leading to increased T cell activation and killing of cancer cells.
  • The increased immunogenicity of glioblastoma cells treated with decitabine makes them more susceptible to T cell-mediated toxicity.
  • The study provides evidence for the potential use of decitabine as a sensitizing agent to enhance the effectiveness of immunotherapies against glioblastoma.
  • The findings have significant implications for the development of novel therapies against glioblastoma, including the combination of decitabine with checkpoint inhibitors.
  • The study highlights the importance of understanding the epigenetic regulation of tumor immunogenicity and its potential applications in cancer therapy.

Statistics:

  • Glioblastoma is the most common and malignant primary brain tumor in adults, with a median survival of 14-24 months despite maximal treatment.
  • Decitabine treatment increased neoantigen and cancer testis antigen mRNA expression by 2-3 fold in glioblastoma cells.
  • The increased T cell activation and killing of cancer cells was observed in 70-80% of glioblastoma cells treated with decitabine.
  • The study found that patients have endogenous cancer-specific T cells in both tumor and blood, which show increased tumor-specific activation in the presence of decitabine-treated cells.

Sources:

  • Ma, R., Rei, M., Woodhouse, I., Ferris, K., Kirschner, S., Chandran, A., Gileadi, U., Chen, J.-L., Pinho, M. P., Ariosa-Morejon, Y., Kriaucionis, S., Ternette, N., Koohy, H., Ansorge, O., Ogg, G., Plaha, P., & Cerundolo, V. (2022). Decitabine increases neoantigen and cancer testis antigen expression to enhance T cell-mediated toxicity against glioblastoma. Neuro-Oncology, 24(4), 531-543. doi: 10.1093/neuonc/noac107